We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Subcutaneous guselkumab induction and maintenance ...
50 mg dose of once-daily obefazimod achieved clinically meaningful improvements, across all endpoints, regardless of prior inadequate response to advanced therapies (AT-IR) Study Population: A total ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results